Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | UCART19 |
| Trade Name | |
| Synonyms | S68587|ALLO-501|TCR/CD52-deficient RQR8+ CD19-CART |
| Drug Descriptions |
UCART19 are allogeneic T-cells engineered to knockout TCR alpha and CD52, and co-express a chimeric antigen receptor targeting CD19 and Rqr8, which demonstrates anti-tumor activity (J Clin Oncol 33, 2015 (suppl; abstr 3069)). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | C137819 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| UCART19 | UCART19 | 0 | 3 |